Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Ford, Nathan ^a   Wilson, David ^a   Chaves, Gabriela Costa ^a   Lotrowska, Michel ^a   Kijtiwatchakul, Kannikar ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Access; Antiretrovirals; Brazil; Patent protection; Thailand

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CLOPIDOGREL; DIDANOSINE; EFAVIRENZ; FLUCONAZOLE; GANCICLOVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VALGANCYCLOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRAZIL; COMBINATION CHEMOTHERAPY; COST OF ILLNESS; CRYPTOCOCCOSIS; DEVELOPING COUNTRY; DRUG CONTROL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG INDUSTRY; DRUG MANUFACTURE; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENSING; MONOTHERAPY; ORGANIZATION AND MANAGEMENT; PATENT; PRIORITY JOURNAL; THAILAND;

ANTI-HIV AGENTS; BRAZIL; DEVELOPING COUNTRIES; DRUG COSTS; DRUGS, GENERIC; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; PATENTS; THAILAND;

EID: 34447329578     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279703.78685.a6     Document Type: Article

References (51)

1. World Health Organizaion. 3 by 5 progress report. Geneva: WHO; March 2006.
2. Levi GC, Vitoria MA. Fighting against AIDS: the Brazilian experience. AIDS 2002; 16:2378-2383.
3. Scheffer M, Salazar AL, Grou K. Medicines through court: a study on access to new medicines and examinations to HIV/AIDS in Brazil by using legal actions. Série legislação 3. Ministério da Saúde, Brasília. Available at: http://www.saberviver.org.br/pdf/ remedio_via_justica.pdf. Accessed: May 2007.
4. Oliveira MA, Esher A. Universal access to treatment for people living with HIV and AIDS in Brazil. In: Bermudez JAZ, Oliveira MA, Esher A, editors. Acceso a medicamentos: derecho fundamental, papel del estado. Rio de Janeiro: ENSP; 2004. pp. 233-250.
5. Galvão J. Access to antiretroviral drugs in Brazil. Lancet 2002; 360:1862-1865.
6. Anon. Response magazine +2005: experiences of the Brazilian AIDS programme. Brasilia: Ministry of Health, Brazilian Program for STD/AIDS; 2005.
7. Kunanusont C. An antiretroviral program: Thailand's experience. In: van Praag E, Fernyak S, Katz AM, editors. The implications of antiretroviral treatments. WHO/ASD/97.2. Geneva: World Health Organization; 1997. pp. 109-113.
8. Prescott N. Economic analysis of antiretroviral treatment options in Thailand. In: Proceedings of the Third International Conference on AIDS in Asia and the Pacific. Chiang Mai, Thailand, 17-21 September 1995. pp. 88-98.
9. UNAIDS. Strengthening national response in ART provision through exchange visits and technical network development between Thailand and Brazil. Report of the Thai Delegation. UNAID/WHO/MSF/Oxfam, StarChine Creation, Bangkok, June 2003; 53 pp.
10. Revenga A, Over M, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, Thanprasertsuk S. The economics of effective AIDS treatment: evaluating policy options for Thailand. Washington, DC, USA: The World Bank; 2006.
11. United Nations Development Programme. Human development report. New York: United Nations; 2006.
12. Ministy of Health. Epidemiological Bulletin, 2006. Available at: http://www.aids.gov.br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891- AD36-1903553A3174%7D/%7B6B12D137-92DF-4CF5-A35A-482AED64CBC0%7D/ BOLETIM2006internet.pdf. Accessed: May 2007.
13. Ministério da Saúde. Monitoraids, 2006. Available at: www.aids.gov.br. Accessed: May 2007.
14. Bermudez JAZ, Oliveira MA. Essential medicines and AIDS care in Brazil: recent lessons learnt. In: Improving access to care in developing countries:lessons from practice, research, resources and partnerships. Joint United Nations Programme on HIV/AIDS (UNAIDS)/WHO/French Ministry of Foreign Affairs; 2002.
15. Granjeiro A, Teixieira L, Bastos FI, Teixeira P. Sustainability of Brazilian policy for access to antiretroviral drugs. Rev Saúde Pública 2006; 40 (Suppl.). Available at: http://www.scielo.br/pdf/ rsp/v40s0/en_09.pdf. Accessed: May 2007.
16. Ford N, Wilson D, Bunjumnong O, von Schoen Angerer T. The role of civil society in protecting public health over commercial interests: lessons from Thailand. Lancet 2004; 363:560-563.
17. World Trade Organization. Frequently asked questions about TRIPS. Which countries are using the general transition periods? Available at: http://www.wto.org/english/tratop_e/trips_e/tripfq_e.htm#Transition. Accessed: May 2007.
18. Oliveira MA, Chaves GC, Epsztejn R. Brazilian intellectual property legislation. In: Jorge A, Bermudez M, Auxiliadora O, editors. Intellectual property in the context of the WTO TRIPS Agreement: challenges for public health. Rio de Janeiro: Escola Nacional de Saúde Pública; 2004.
19. Basso M. Intervention of health authorities in patent examination: the Brazilian practice of the prior consent. Int J Intellectual Property Manage 2006; 1:54-74.
20. Chaves GC, Oliveira MA. A proposal for measuring the degree of public health sensitivity of patent legislation in the context of the WTO TRIPS Agreement. Bull WHO 2007; 85:49-56.
21. Von Schoen-Angerer T, Limpananont J. US pressure on less-developed countries. Lancet 2001; 358:245.
22. Velasquez G, Boulet P. Globalization and access to drugs - perspectives on the WTO/TRIPS Agreement. WHO/DAP/98.9 revised. Geneva: WHO; 1999.
23. Brazil, 1996. Act 9.279, May 14 1996. Establishes rights and obligations related to industrial property. Brasilia: Diário Oficial da União of May 15 1996.
24. Brazil, 1996. Act 9.313, November 13 1996. Establishes free medicines distribution to individuals with HIV and AIDS. Brasilia: Diário Oficial da União of November 14 1996.
25. Working Group on Intellectual Property (GTPI) of the Brazilian Network for the Integration of Peoples (Rebrip), 2006. Why Brazil pays more for important medicines to public health? Available at: http://www.abiaids.org.br/ media/patentes_GTPI.pdf. Accessed: May 2007.
26. Médecins Sans Frontières. Drug patents under the spotlight: Sharing practical knowledge about pharmaceutical patents. Geneva: MSF; May 2003. Available at: http://www.accessmed-msf.org/documents/ Patent%20report%20.pdf. Accessed: May 2007.
27. The Economist Intelligence Unit. Thailand country report: 2nd quarter 1998. London: EIU; 1999.
28. Limpananont J. Thailand: the impact of pressure from the US - patents, pills and public health: can TRIPS deliver? London: Panos; 2002. pp. 41-43.
29. Kuanpoth J, Limpananont J, Narintarakul K, Silarak B, Taneewuth S, Lianchamroon W, et al. Free Trade Agreements and their impact on Developing Countries: the Thai experience. Nonthaburi, Thailand: FTA Watch; September 2005.
30. Aongsonwang S. Pharmaceutical patent law: a law by transnational companies - Thailand's experience. Paper presented at NGO meeting on compulsory licensing of essential medical technologies. Geneva, 1999.
31. Office of the United States Trade Representative. National trade estimate report on foreign trade barriers. Washington, DC: US Trade Representative; 1999.
32. Wilson D, Cawthorne P, Ford N, Aongsonwang S. Global trade and access to medicines: AIDS treatments in Thailand. Lancet 1999; 354:1893-1895.
33. Calmy A, Pascual F, Shettle S, de la Vega FG, Ford N. The Lancet Red: a missed opportunity. Lancet 2006; 368 (9541):1063.
34. World Health Organization. External review of the health sector response to HIV/AIDS in Thailand. New Delhi: MOPH, WHOSEA; August 2005.
35. Bermudez JAZ, Oliveira MA, Chaves GC. 2004. The WTO TRIPS Agreement and challenges for public health. In: Bermudez JAZ, Oliveira MA, Esher A, editors. Access to medicines: fundamental right, the role of the State. Rio de Janeiro: ENSP; 2004. pp. 69-88.
36. Later changed through the Decree 4.830, September 4th 2003.
37. Pinheiro E, Vasan A, Kim JY, Leed E, Guimier J-M, Perriens J. Examining the production costs of antiretroviral drugs. AIDS 2006; 20:1745-1752.
38. Fortunak JM, Antunes OAC. ARVs production in Brazil - an evaluation. 2006. Available at: http://www.abiaids.org.br/media/ARV.pdf. Accessed: May 2007.
39. Astor M. Brazil AIDS drug negotiations break down. Associated Press, 4 May 2007.
40. Anon. HIV drug fears. Hundreds rally at Glaxo office. UK firm's move for patent on Combid is 'a threat to access of cheap medicines'. Nation, 8 August 2006. Available at: http://www.gsk.com/media/archive. htm. Accessed: May 2007.
41. Cawthorne P, Dayal A. Thailand still shows the way on HIV/AIDS. Nation, 2 December 2006. Available at: http://www.nationmultimedia.com/ 2006/12/02/opinion/opinion_30020541.php. Accessed: May 2007.
42. Cawthorne P, Ford N, Limpananont J, Tienudom N, Purahong W. WHO must defend patients' interests, not industry. Lancet 2007; 369:974-975.
43. Gerhardsen TIS. Thailand compulsory license on AIDS drug prompts policy debate. Intellectural Property Watch, 23 December 2006. Available at: http://www.ip-watch.org/weblog/index.php?p=499&res= 1024_ff&print=0. Accessed: May 2007.
44. Facts and evidences on the ten burning issues related to the government use of patents on three patented essential drugs in Thailand. Issued by the Ministry of Public Health and the National Health Security Office, Nonthaburi, Thailand, February 2007. Available at: http://www.moph.go.th/hot/ White%20Paper%20CL-EN.pdf. Accessed: 3 May 2007.
45. Open Letter to Miles White, CEO of Abbott, 15 March 2006. Available at: http://www.accessmed-msf.org/documents/April%205%20Letter%20to%20Abbott.pdf. Accessed: May 2007.
46. Steinbrook R. Thailand and the compulsory licensing of efavirenz. N Engl J Med 2007; 356:544-546.
47. Wong-Anan N. Thailand issues more compulsory drugs licences. Reuters, 25 January 2007.
48. Wongruang P. Move to break drug patents lauded. Bangkok Post, 3 February 2007.
49. Cawthorne P, Ford N, Wilson D, Kijtiwatchakul K, Purahong V, Tianudom N, Nacapew S. Access to drugs: the case of Abbott in Thailand. Lancet Infect Dis 2007 Jun; 7(6):373-374.
50. Anon. Status downgrade: outrage grows at US trade pressure. Nation, 3 May 2007. Available at: http://www.nationmultimedia.com/search/ page.news.php?clid=2&id=30033264. Accessed: 7 May 2007.
51. Over M, Heywood P, Gold J, Gupta I, Hira S, Marseille E. Prevention and treatment in India: modeling the costs and consequences. Washington, DC: World Bank; 2004.